Banner Image

News

  Secondary Navigation

Advanced Cell Diagnostics is a Finalist for the 2013 Red Herring Top 100 North America Award

2013 June 10 | Posted by ACD

HAYWARD, CALIFORNIA–Advanced Cell Diagnostics, Inc. (ACD), a biotechnology company that manufactures life science reagents for basic biomarker research and cell and tissue-based diagnostic tests, announced today it had been selected as a Finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private ventures from the North American business region.

"We are very pleased to be named a Red Herring Top 100 North America Finalist and be recognized along with other innovative startups. ," said Dr. Yuling Luo, founder and chief executive officer of ACD. Dr. Luo added, "This recognition further validates our innovative RNAscope® technology that will unlock the full potential of RNA biomarkers for personalized medicine."

Red Herring has been selecting the most exciting and promising start-ups and "scale ups" since 1995. Finalists are still evaluated individually from a large pool of hundreds of candidates based across North America. Twenty major criteria underlie the scoring and process. They include, among others: the candidate company's addressable market size, its IP and patents, its financing, the proof of concept, trailing revenues and management's expertise. Each company goes through an individual interview after filling out a thorough submission, complemented by a due diligence. The list of finalists often includes the best performing and prominent companies of that year.

2013 will be remembered as a special vintage. "The finalists list confirms the excellent choices made by entrepreneurs and VCs and the start-ups' solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States’ entrepreneurial excellence," said Alex Vieux, publisher and CEO of Red Herring.

Finalist selections for the 2013 edition of the Red Herring 100 North America award are based upon technological innovation, management strength, market size, investor record, customer acquisition and financial health. During the several months leading up to the announcement, hundreds of companies in the fields of security, Web 2.0, software, hardware, life sciences, cloud, mobile and others completed their submissions to qualify for the award.

About Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. RNAscope® assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com.

Press Contact:
Steve Chen, Ph.D.
Chief Operating Officer
(510) 259-9802
schen@acdbio.com

Download Press Release (PDF)

Feedback
Tracker Pixel for Entry